...
首页> 外文期刊>Virology >Lactococcus lactis displayed neuraminidase confers cross protective immunity against influenza A viruses in mice
【24h】

Lactococcus lactis displayed neuraminidase confers cross protective immunity against influenza A viruses in mice

机译:乳酸乳球菌显示神经氨酸酶赋予小鼠抗甲型流感病毒的交叉保护性免疫

获取原文
获取原文并翻译 | 示例
           

摘要

Influenza A viruses pose a serious threat to public health. Current influenza A vaccines predominantly focus on hemagglutinin (HA) and show strain-specific protection. Neuraminidase (NA) is much Jess studied in the context of humoral immunity against influenza A viruses. The purpose of this study is to evaluate the cross protective immunity of NA presented on Lactococcus lactis (Llactis) surface against homologous and heterologous influenza A viruses in the mouse model. L.lactis/pNZ8110-pgsA-NA was constructed in which pgsA was used as an anchor protein. Mice vaccinated orally with LlactislpNZ8110pgsA-NA could elicit significant NA-specific serum IgG and mucosa IgA antibodies, as well as neuraminidase inhibition (NI) titers. Importantly, Llactis/pNZ8110-pgsA-NA provided 80% protection against H5N1, 60% protection against H3N2 and H1N1, respectively. These findings suggest that recombinant L./actis/pNZ110-pgsA-NA in the absence of adjuvant via oral administration can be served as an effective vaccine candidate against diverse strains of influenza A viruses. (C) 2014 Elsevier Inc. All rights reserved.
机译:甲型流感病毒严重威胁公共健康。当前的甲型流感疫苗主要集中于血凝素(HA)并显示出菌株特异性保护。在针对甲型流感病毒的体液免疫中,神经氨酸酶(NA)的研究非常广泛。这项研究的目的是评估呈现在小鼠乳酸乳球菌(乳酸菌)表面的NA对同源和异源甲型流感病毒的交叉保护免疫。构建了乳酸乳球菌/ pNZ8110-pgsA-NA,其中pgsA用作锚定蛋白。口服LlactislpNZ8110pgsA-NA疫苗的小鼠可引起明显的NA特异性血清IgG和粘膜IgA抗体,以及神经氨酸酶抑制(NI)效价。重要的是,Llactis / pNZ8110-pgsA-NA分别提供了针对H5N1的80%保护,针对H3N2和H1N1的60%保护。这些发现表明,在不存在通过口服给药的佐剂的情况下,重组L./actis/pNZ110-pgsA-NA可以作为针对多种A型流感病毒的有效疫苗候选物。 (C)2014 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号